Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 2.550-2.650 for the period, compared to the consensus earnings per share estimate of 2.590. The company issued revenue guidance of $16.8 billion-$17.0 billion, compared to the consensus revenue estimate of $16.9 billion.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Scotiabank started coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective on the stock. Bank of America upped their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.67.

Teva Pharmaceutical Industries Trading Down 1.5%

Shares of NYSE TEVA opened at $32.03 on Monday. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $32.91. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The business’s 50 day moving average is $28.04 and its two-hundred day moving average is $21.60. The stock has a market capitalization of $36.73 billion, a P/E ratio of 53.38, a PEG ratio of 1.86 and a beta of 0.66.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares in the company, valued at $11,934,450. This trade represents a 28.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 622,060 shares of company stock worth $17,076,965. 0.55% of the stock is owned by company insiders.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva agreed with Royalty Pharma on up to $500 million of funding to accelerate development of its anti‑IL‑15 antibody TEV‑‘408 for vitiligo; emerging Phase 1b data reportedly support IL‑15 as a therapeutic target and Teva expects to share trial results during 2026. This is a major non‑dilutive financing and creates a clear clinical catalyst. Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
• Positive Sentiment: Truist raised its price target on TEVA to $36 from $32 and kept a Buy rating, citing continued strength in the affordable medicines theme — a supportive analyst view that can lift investor sentiment and valuation expectations. Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32
• Positive Sentiment: A Wall Street Zen upgrade to Strong‑Buy adds to positive analyst/quant sentiment and may attract momentum flows and new investors. Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to Strong-Buy at Wall Street Zen
• Positive Sentiment: Coverage noting high institutional ownership and recent weekly gains (stock was up about 3.4% last week) underscores demand from large holders and recent momentum that can support the share price going forward. Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) high institutional ownership speaks for itself as stock continues to impress, up 3.4% over last week
• Neutral Sentiment: Teva’s CEO Richard Francis will present at the J.P. Morgan Healthcare Conference on Jan. 13 to outline the “pivot to growth” strategy — this is an opportunity for management to provide updates, but impact depends on whether new financial or clinical detail is disclosed. Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. Wellington Management Group LLP lifted its position in shares of Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the period. Polar Capital Holdings Plc bought a new position in Teva Pharmaceutical Industries in the third quarter worth approximately $80,983,000. Alyeska Investment Group L.P. raised its stake in Teva Pharmaceutical Industries by 145.9% in the third quarter. Alyeska Investment Group L.P. now owns 5,976,035 shares of the company’s stock worth $120,716,000 after buying an additional 3,545,577 shares in the last quarter. Viking Global Investors LP lifted its holdings in Teva Pharmaceutical Industries by 15.4% during the second quarter. Viking Global Investors LP now owns 11,681,333 shares of the company’s stock worth $195,779,000 after buying an additional 1,555,855 shares during the period. Finally, Bank of America Corp DE boosted its position in Teva Pharmaceutical Industries by 19.6% during the 2nd quarter. Bank of America Corp DE now owns 9,004,963 shares of the company’s stock valued at $150,923,000 after acquiring an additional 1,473,740 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.